Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study

Clinical and Experimental Rheumatology

Volumn 34, Issue 3, 2016, Pages 489-499

  Nüßlein, Hubert G ^a   Alten, Rieke ^b   Galeazzi, Mauro ^c   Lorenz, Hanns Martin ^d   Nurmohamed, Michael T ^e   Bensen, William G ^f   Burmester, Gerd R ^g   Peter, Hans Hartmut ^h   Peichl, Peter ⁱ   Pavelka, Karel ^j   Chartier, Mélanie ^k   Poncet, Coralie ^l   Rauch, Christiane ^m   Le Bars, Manuela ^m  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Schlosspark Klinik   (Germany)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ST JOSEPH S HOSPITAL   (Canada)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ Evangelisches Krankenhaus Vienna   (Austria)

^j INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^k Chiltern International   (France)

^l Docs International   (France)

^m BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Abatacept; Biological therapy; Cohort studies; Cyclic citrullinated peptide; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

ABATACEPT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; OCRELIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BASAL CELL CARCINOMA; BODY MASS; BOWEN DISEASE; BRAIN CANCER; BRAIN TUMOR; BREAST CARCINOMA; CANADA; CARDIOVASCULAR DISEASE; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL PRACTICE; CLINICAL STUDY; CLUSTER ANALYSIS; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DAS28; DEMOGRAPHY; DIGESTIVE SYSTEM CANCER; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; EUROPE; FEMALE; FISHER EXACT TEST; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX; HEART DISEASE; HUMAN; HYPERSENSITIVITY; INFECTION; INTERNATIONAL COOPERATION; KAPLAN MEIER METHOD; LOW DISEASE ACTIVITY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOTHERAPY; MORBIDITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NONHODGKIN LYMPHOMA; OBSERVATIONAL STUDY; PELVIS TUMOR; PHYSICAL PARAMETERS; PHYSICIAN; PHYSICIAN DISCRETION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REAL WORLD STUDY; REGRESSION ANALYSIS; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT RETENTION; TUBERCULOSIS; UNIVARIATE ANALYSIS; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; AGED; ARTHRITIS, RHEUMATOID; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATIENT ACUITY; TIME FACTOR;

ABATACEPT; ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT ACUITY; PROGNOSIS; RHEUMATOID FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84982839118     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. DAIEN CI, MOREL J: Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm 2014; 2014: 386148.
2. GOTTENBERG JE, RAVAUD P, CANTAGREL A et al.: Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis 2012; 71: 1815-9.
3. LEFFERS HC, OSTERGAARD M, GLINTBORG B et al.: Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011; 70: 1216-22.
4. SCARSI M, ZIGLIOLI T, AIRO' P: Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 2011; 38: 2105-11.
5. SAEVARSDOTTIR S, STAWIARZ L, TURESSON C, LINBLAD S: Previous biological therapies influence drug survival in rheumatoid arthritis patients starting abatacept treatment 2006-2012. Ann Rheum Dis 2013; 72: 626.
6. FINCKH A, IANNONE F, REINO JG et al.: The impact of inadequate response to prior biologic agents on abatacept drug retention in rheumatoid arthritis patients. A pan-European analysis of RA registries. Arthritis Rheum 2013; 65: S217.
7. GOTTENBERG JE, NETO D, GOMEZ-REINO J et al.: Positivity for rheumatoid factor and anticyclic citrullinated peptide is associated with better drug retention of abatacept: data from a pan-European analysis of RA registries. Ann Rheum Dis 2014; 73 (Suppl. 2): 502.
8. FINCKH A, NETO D, IANNONE F et al.: The impact of patient heterogeneity and socio- economic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD open 2015; 1: e000040.
9. PAPAGORAS C, VOULGARI PV, DROSOS AA: Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev 2010; 9: 574-82.
10. PAPAGORAS C, DROSOS AA: Abatacept: a biologic immune modulator for rheumatoid arthritis. Expert Opin Biol Ther 2011; 11: 1113-29.
11. NüßLEIN H, ALTEN R, GALEAZZI M et al.: Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord 2014; 15: 14.
12. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
13. FRANSEN J, van RIEL PL: The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009; 35: 745-57.
14. FELSON DT, SMOLEN JS, WELLS G et al.: American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011; 70: 404-13.
15. WELLS GA, TUGWELL P, KRAAG GR, BAKER PR, GROH J, REDELMEIER DA: Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993; 20: 557-60.
16. World Health Organization: Global Database on Body Mass Index. Source: http://apps. who.int/bmi/index.jsp?introPage=intro_3. html& . 2014. 7-8-2014. Ref Type: Internet Communication
17. du PAN SM, DEHLER S, CIUREA A, ZISWILER HR, GABAY C, FINCKH A: Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009; 61: 560-8.
18. LINDBLAD S, STAWIARZ L: Gender and previous treatment influence outcomes from abatacept in a 5-year rheumatoid arthritis cohort. Ann Rheum Dis 2012; 71: 383.
19. FORSBLAD-D'ELIA H, BENGTSSON K, KRISTENSEN LE, JACOBSSON LTH: Drug survival, efficacy and predictors for survival on tocilizumab in real-life patients with rheumatoid arthritis; results from the Swedish Biologics Register. Arthritis Rheum 2012; 64: S201.
20. GREENBERG JD, REED G, DECKTOR D et al.: A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012; 71: 1134-42.
21. MAXWELL LJ, SINGH JA: Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2010; 37: 234-45.
22. SCHIFF M, PONCET C, LE BARS M: Efficacy and safety of abatacept therapy for rheumatoid arthritis in routine clinical practice. Int J Clin Rheumatol 2010; 5: 581-91.
23. WEINBLATT ME, MORELAND LW, WESTHOVENS R et al.: Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol 2013; 40: 787-97.
24. NüßLEIN HG, ALTEN R, GALEAZZI M et al.: Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study. BMC Musculoskelet Disord 2015; 16: 176.
25. EMERY P, BURMESTER GR, BYKERK VP et al.: Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis 2015; 74: 19-26.
26. CONNOLLY S, MALDONADO M, SCHIFF M et al.: Modulation of the ACPA fine specificity in patients with RA treated with either abatacept or adalimumab in the AMPLE study. Ann Rheum Dis 2014; 73 (Suppl. 2): 395.
27. FUJII T, SEKIGUCHI M, MATSUI K et al.: Very high titer of anti-citrullinated protein antibodies is associated with the achievement of clinical remission by abatacept in biologicnaïve patients with rheumatoid arthritis (the ABROAD study). Ann Rheum Dis 2013; 72 (Suppl. 3): 889.
28. BUCH MH, RAKIEH C, HENSOR E et al.: An exploratory clinical and imaging study evaluating abatacept in the management of poor prognosis ACPA negative undifferentiated arthritis. Ann Rheum Dis 2014; 73 (Suppl. 2): 678.
29. PIEPER J, HERRATH J, RAGHAVAN S, MUHAMMAD K, VOLLENHOVEN R, MALMSTROM V: CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol 2013; 14: 34.
30. SCARSI M, PAOLINI L, RICOTTA D et al.: Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol 2014; 41: 666-72.
31. CHATZIDIONYSIOU K, LIE E, NASONOV E et al.: Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70: 1575-80.
32. GOTTENBERG J-E, RAVAUD P, BARDIN T et al.: Assessment of real life efficacy of rituximab in rheumatoid arthritis: predicting factors of the therapeutic maintenance and demonstration of a corticosteroid sparing effect in the AutoImmunity and Rituximab registry. Arthritis Rheum 2010; 62 (Suppl. 10): 1790.
33. STRANGFELD A, EVESLAGE M, KEKOW J et al.: Effectiveness of treatment with rituximab depends on autoantibody status results from 2 years of experience in the German biologics register RABBIT. Arthritis Rheum 2009; 60 (Suppl. 10): 1695.
34. QUARTUCCIO L, FABRIS M, SALVIN S et al.: Rheumatoid factor positivity rather than anti- CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2009; 48: 1557-9.
35. LV Q, YIN Y, LI X et al.: The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFa agent treatment in patients with rheumatoid arthritis: a meta-analysis. PLoS ONE 2014; 9: e89442.
36. Adalimumab Summary of Product Characteristics. Source: http://www.ema.europa. eu/docs/en_GB/document_library/EPAR_-_ Product_Information/human/000481/ WC500050870.pdf. Last accessed: 9 January 2013.
37. Certolizumab pegol Summary of Product Characteristics. Source: http://www. ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/ 001037/WC500069763.pdf. Last accessed: 9 January 2013.
38. Golimumab Summary of Product Characteristics. Source: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_ Information/human/000992/WC500052368. pdf. Last accessed: 9 January 2013.
39. Infliximab Summary of Product Characteristics. Source: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_ Information/human/000240/WC500050888. pdf. Last accessed: 9 January 2013.
40. Etanercept Summary of Product Characteristics. Source: http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_ Information/human/000262/WC500027361. pdf. Last accessed: 9 January 2013.
41. PUTRIK P, RAMIRO S, KVIEN TK et al.: Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis 2014; 73: 198-206.
42. PUTRIK P, RAMIRO S, KESZEI AP et al.: Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. Ann Rheum Dis 2016; 75: 540-46
43. NETO D, FINCKH A, IANNONE F et al.: Differences in abatacept use in rheumatoid arthritis patients across Europe: a pan-European database analysis of abatacept in European RA registries. Arthritis Rheum 2013; 65: S1248.
44. FINCKH A, GOMEZ-REINO J, IANNONE F et al.: The impact of DMARD co-therapy on abatacept effectiveness in rheumatoid arthritis patients. A pan-European analysis of RA registries. Ann Rheum Dis 2014; 73 (Suppl. 2): FRI0298.
45. ARIZA-ARIZA R, NAVARRO-SARABIA F, HERNANDEZ-CRUZ B, RODRIGUEZ-ARBOLEYA L, NAVARRO-COMPAN V, TOYOS J: Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46: 529-32.
46. GREMESE E, CARLETTO A, PADOVAN M et al.: Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken) 2013; 65: 94-100.